EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Analysis of Selected Serum Cytokines to Evaluate the Early Efficacy of Benralizumab, Dupilumab, and Mepolizumab in Severe Eosinophilic Asthma Treatment

Aleksandra Niemiec-Górska iD, Łukasz Labus, Sylwia Mielcarska iD, Joanna Glück iD, Zenon Czuba iD, Marcin Cyrnek, Olga Branicka iD, Barbara Rymarczyk iD, Radosław Gawlik

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms262010075 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Aleksandra Niemiec-Górska und 8 weiteren Autor:innen. Beteiligte Einrichtung: Chair and Department of Internal Medicine, Allergology and Clinical Immunology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia,…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Asthma, Cytokines, Anti-Asthmatic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Silesia, Medical University of Silesia, Katowice, Poland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Severe asthma is a chronic, difficult-to-treat disorder that significantly affects quality of life, and oral glucocorticosteroids are usually required. Many patients suffering from severe asthma exhibit T2 inflammation and may benefit from biological treatment. This study aims to evaluate changes in cytokine concentrations during therapy with benralizumab, dupilumab, and mepolizumab in severe eosinophilic asthma. Materials and Methods: In this prospective, single-center study, 39 patients with severe eosinophilic asthma received treatment with one of the above-mentioned biologics. Parameters, such as the cytokine profile (Human Th9/Th17/Th22 Luminex, Performance Assay 18-plex Fixed Panel, R&D Systems, Minneapolis, MN, USA) and additionally the Asthma Control Questionnaire (ACQ), mini-Asthma Quality of Life Questionnaire (mini-AQLQ), spirometry (FEV1, FEV/FVC), FeNO, and functional status, were assessed at baseline and after 3–4 months of therapy.

Results

The biologic therapies demonstrated diverse effects on inflammatory biomarkers. Dupilumab showed the most pronounced decreases in CD40L, IL-6, and FeNO in comparison to other drugs. In turn, the greatest decrease in TNF-α concentration was observed in the group treated with mepolizumab.

Conclusion

Changes in cytokine concentrations highlight the heterogenous immunomodulatory mechanisms of biologics and support personalized strategies based on inflammatory profiles. However, the results should be interpreted with prudence, as the concentrations of cytokines in blood serum fluctuate and the study sample size is small.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAsthmaCytokinesAnti-Asthmatic AgentsHumansFemaleMaleMiddle AgedAdultProspective StudiesQuality of LifeBiomarkersTreatment OutcomeAged

Stichwörter der Autor:innen

benralizumabdupilumabeosinophilic asthmamepolizumab cytokines

Substanzen

Antibodies, Monoclonal, HumanizedmepolizumabbenralizumabdupilumabCytokinesAnti-Asthmatic AgentsBiomarkers

Autor:innen und Institutionen

  • Chair and Department of Internal Medicine, Allergology and Clinical Immunology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Medyków 14 Street, 40-752 Katowice, Poland.
  • Doctoral School, Medical University of Silesia, 40-752 Katowice, Poland.
  • Department of Lung Diseases and Tuberculosis, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 40-752 Katowice, Poland.
  • Chair and Department of Medical and Molecular Biology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 40-752 Katowice, Poland.
  • Chair and Department of Microbiology and Immunology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 40-752 Katowice, Poland.
  • Chair and Department of Internal Medicine and Clinical Pharmacology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, 40-752 Katowice, Poland.

ORCID-Profile: Aleksandra Niemiec-Górska, Sylwia Mielcarska, Joanna Glück, Zenon Czuba, Olga Branicka, Barbara Rymarczyk

Förderung

  • Medical University of Silesia
  • Medical University of Silesia, Katowice, Poland

Zitieren

APA

Niemiec-Górska, A., Labus, Ł., Mielcarska, S., Glück, J., Czuba, Z., Cyrnek, M., Branicka, O., Rymarczyk, B., & Gawlik, R. (2025). Analysis of Selected Serum Cytokines to Evaluate the Early Efficacy of Benralizumab, Dupilumab, and Mepolizumab in Severe Eosinophilic Asthma Treatment. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262010075

Vancouver

Niemiec-Górska A, Labus Ł, Mielcarska S, Glück J, Czuba Z, Cyrnek M, et al. Analysis of Selected Serum Cytokines to Evaluate the Early Efficacy of Benralizumab, Dupilumab, and Mepolizumab in Severe Eosinophilic Asthma Treatment. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262010075

BibTeX
@article{NiemiecGrska2025,
  author = {Niemiec-Górska, Aleksandra and Labus, Łukasz and Mielcarska, Sylwia and Glück, Joanna and Czuba, Zenon and Cyrnek, Marcin and Branicka, Olga and Rymarczyk, Barbara and Gawlik, Radosław},
  title = {Analysis of Selected Serum Cytokines to Evaluate the Early Efficacy of Benralizumab, Dupilumab, and Mepolizumab in Severe Eosinophilic Asthma Treatment},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms262010075}
}
Kostenlos starten →